Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF- kB activation

Molecules and Cells

Volumn 37, Issue 8, 2014, Pages 585-591

  Lee, Su Ui ^a   Ahn, Kyung Seop ^a   Sung, Min Hee ^a   Park, Ji Won ^a   Ryu, Hyung Won ^a   Lee, Hyun Jun ^a   Hong, Sung Tae ^b   Oh, Sei Ryang ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

ADRB2; Indacaterol; Invasion; MMP 9; NF kB

Indexed keywords

GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDACATEROL; ADRB2 PROTEIN, HUMAN; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; I KAPPA B KINASE; INDAN DERIVATIVE; LUCIFERASE; QUINOLONE DERIVATIVE; RETINA S ANTIGEN;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENE TRANSLOCATION; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN ANALYSIS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ARRESTINS; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; I-KAPPA B KINASE; INDANS; LUCIFERASES; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; PROTEIN INTERACTION MAPPING; PROTEIN TRANSPORT; QUINOLONES; RECEPTORS, ADRENERGIC, BETA-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84929626752     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0076     Document Type: Article

References (37)

1. Ball, D.I., Brittain, R.T., Coleman, R.A., Denyer, L.H., Jack, D., Johnson, M., Lunts, L.H., Nials, A.T., Sheldrick, K.E., and Skidmore, I.F. (1991). Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol. 104, 665-671.
2. Barnes, P.J., and Pride, N.B. (1983). Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br. J. Clin. Pharmacol. 15, 677-682.
3. Catley, M.C., Chivers, J.E., Holden, N.S., Ba rnes, P.J., and Newton, R. (2005). Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br. J. Pharmacol. 145, 114-122.
4. Chetty, A., Cao, G.J., Severgnini, M., Simon, A., Warburton, R., and Nielsen, H.C. (2008). Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L584-592.
5. Churg, A., Wang, R.D., Tai, H., Wang, X., Xie, C., and Wright, J.L. (2004). Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am. J. Respir. Crit. Care Med. 170, 492-498.
6. Churg, A., Wang, R., Wang, X., Onnervik, P.O., Thim, K., and Wright, J.L. (2007). Effect of an MMP-9/MMP-12 inhibitor on smokeinduced emphysema and airway remodelling in guinea pigs. Thorax 62, 706-713.
7. Cullum, V.A., Farmer, J.B., Jack, D., and Levy, G.P. (1969). Salbutamol: a new, selective beta-adrenoceptive receptor stimulant. Br. J. Pharmacol. 35, 141-151.
8. Donohue, J.F., Fogarty, C., Lotvall, J., Mahler, D.A., Worth, H., Yorgancioglu, A., Iqbal, A., Swales, J., Owen, R., Higgins, M., et al. (2010). Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 182, 155-162.
9. Edwards, M.R., Bartlett, N.W., Clarke, D., Birrell, M., Belvisi, M., and Johnston, S.L. (2009). Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther. 121, 1-13.
10. Finlay, G.A., Russell, K.J., McMahon, K.J., D’Arcy E M., Masterson, J.B., FitzGerald, M.X., and O’Connor, C.M. (1997). Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52, 502-506.
11. Gao, H., Sun, Y., Wu, Y., Luan, B., Wang, Y., Qu, B., and Pei, G. (2004). Identification of beta-arrestin2 as a G protein-coupled receptor stimulated regulator of NF-kappaB pathways. Mol. Cell 14, 303-317.
12. Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Ann. Rev. Immunol. 16, 225-260.
13. Hanania, N.A., Chapman, K.R., and Kesten, S. (1995). Adverse effects of inhaled corticosteroids. Am. J. Med. 98, 196-208.
14. Johnson, M. (2006) Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J. Allergy Clin. Immunol. 117, 18-24; quiz 25.
15. Klein, G., Vellenga, E., Fraaije, M.W., Kamps, W.A., and de Bont, E.S. (2004). The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 50, 87-100.
16. Lee, S.U., Choi, Y.H., Kim, Y.S., Park, S.J., Kwak, H.B., Min, Y.K., Kim, H.N., Lim, K.E., Choi, J.Y., Rhee, M., et al. (2010). Physcion-8-O-beta-D-glucopyranoside enhances the commitment of mouse mesenchymal progenitors into osteoblasts and their differentiation: Possible involvement of signaling pathways to activate BMP gene expression. J. Cell. Biochem. 109, 1148-1157.
17. Lee, S.U., In, H.J., Kwon, M.S., Park, B.O., Jo, M., Kim, M.O., Cho, S., Lee, S., Lee, H.J., Kwak, Y.S., et al. (2013). beta-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear Factor-kappaB. Biol. Pharm. Bull. 36, 1754-1759.
18. Lefkowitz, R.J., and Shenoy, S.K. (2005). Transduction of receptor signals by beta-arrestins. Science 308, 512-517.
19. Ling, H., Zhang, Y., Ng, K.Y., and Chew, E.H. (2011). Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factorkappaB-dependent matrix metalloproteinase-9 expression. Breast Cancer Res. Treat. 126, 609-620.
20. Loganathan, R.S., Stover, D.E., Shi, W., and Venkatraman, E. (2006). Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 129, 1305-1312.
21. Lora, J.M., Zhang, D.M., Liao, S.M., Burwell, T., King, A.M., Barker, P.A., Singh, L., Keaveney, M., Morgenstern, J., Gutierrez-Ramos, J.C., et al. (2005). Tumor necrosis factor-alpha triggers mucus production in airway epithelium through an IkappaB kinase betadependent mechanism. J. Biol. Chem. 280, 36510-36517.
22. Luan, B., Zhang, Z., Wu, Y., Kang, J., and Pei, G. (2005). Betaarrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. EMBO J. 24, 4237-4246.
23. Lundblad, L.K., Thompson-Figueroa, J., Leclair, T., Sullivan, M.J., Poynter, M.E., Irvin, C.G., and Bates, J.H. (2005). Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am. J. Respir. Crit. Care Med. 171, 1363-1370.
24. Luttrell, L.M., and Lefkowitz, R.J. (2002). The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115, 455-465.
25. Matera, M.G., Calzetta, L., and Cazzola, M. (2010). TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm. Pharmacol. Ther. 23, 121-128.
26. Muroski, M.E., Roycik, M.D., Newcomer, R.G., Van den Steen, P.E., Opdenakker, G., Monroe, H.R., Sahab, Z.J., and Sang, Q.X. (2008). Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9, 34-46.
27. Naline, E., Trifilieff, A., Fairhurst, R.A., Advenier, C., and Molimard, M. (2007). Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur. Respir. J. 29, 575-581.
28. Oh, D.Y., Talukdar, S., Bae, E.J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W.J., Watkins, S.M., and Olefsky, J.M. (2010). GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142, 687-698.
29. Sekine, Y., Katsura, H., Koh, E., Hiroshima, K., and Fujisawa, T. (2012). Early detection of COPD is important for lung cancer surveillance. Eur. Respir. J. 39, 1230-1240.
30. Shenoy, S.K., and Lefkowitz, R.J. (2003). Multifaceted roles of betaarrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem. J. 375, 503-515.
31. Tashkin, D.P., and Ferguson, G.T. (2013). Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res. 14, 49.
32. van der Molen, T., Postma, D.S., Turner, M.O., Jong, B.M., Malo, J.L., Chapman, K., Grossman, R., de Graaff, C.S., Riemersma, R.A., and Sears, M.R. (1997). Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian formoterol study investigators. Thorax 52, 535-539.
33. Vestbo, J., Prescott, E., and Lange, P. (1996). Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City heart study group. Am. J. Respir. Crit. Care Med. 153, 1530-1535.
34. Watanabe, T., Jono, H., Han, J., Lim, D.J., and Li, J.D. (2004). Synergistic activation of NF-kappaB by nontypeable Haemophilus influenza and tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA 101, 3563-3568.
35. Welte, T. (2009). Optimising treatment for COPD--new strategies for combination therapy. Int. J. Clin. Pract. 63, 1136-1149.
36. Witherow, D.S., Garrison, T.R., Miller, W.E., and Lefkowitz, R.J. (2004). beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc. Natl. Acad. Sci. USA 101, 8603-8607.
37. Yorgancioglu, A. (2012). Indacaterol in chronic obstructive pulmonary disease: an update for clinicians. Ther. Adv. Chronic. Dis. 3, 25-36.